Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XL647 in Previously Untreated NSCLC
NCT00364780Phase 2Completed
- Sponsor
- Kadmon
- Start
- Jul 2006
- Primary completion
- May 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tesevatinib in non-small cell lung cancer (NSCLC), sponsored by Kadmon. Started Jul 2006; status: completed.
02
Drugs
tesevatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00364780.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00364780.